Structure Based Docking and Molecular Dynamic Studies of Plasmodial Cysteine Proteases Against a South African Natural Compound and Its Analogs

Overview

Journal Sci Rep

Specialty Science

Date 2016 Apr 1

PMID 27030511

Citations 32

Authors

Thommas M Musyoka

Aquillah M Kanzi

Kevin A Lobb

Ozlem Tastan Bishop

Affiliations

Soon will be listed here.

Abstract

Identification of potential drug targets as well as development of novel antimalarial chemotherapies with unique mode of actions due to drug resistance by Plasmodium parasites are inevitable. Falcipains (falcipain-2 and falcipain-3) of Plasmodium falciparum, which catalyse the haemoglobin degradation process, are validated drug targets. Previous attempts to develop peptide based drugs against these enzymes have been futile due to the poor pharmacological profiles and susceptibility to degradation by host enzymes. This study aimed to identify potential non-peptide inhibitors against falcipains and their homologs from other Plasmodium species. Structure based virtual docking approach was used to screen a small non-peptidic library of natural compounds from South Africa against 11 proteins. A potential hit, 5α-Pregna-1,20-dien-3-one (5PGA), with inhibitory activity against plasmodial proteases and selectivity on human cathepsins was identified. A 3D similarity search on the ZINC database using 5PGA identified five potential hits based on their docking energies. The key interacting residues of proteins with compounds were identified via molecular dynamics and free binding energy calculations. Overall, this study provides a basis for further chemical design for more effective derivatives of these compounds. Interestingly, as these compounds have cholesterol-like nuclei, they and their derivatives might be well tolerated in humans.

Citing Articles

Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors.

Arthur M, Hanson G, Broni E, Sakyi P, Mensah-Brown H, Miller 3rd W Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861069 PMC: 11768234. DOI: 10.3390/ph18010006.

Machine learning and molecular docking prediction of potential inhibitors against dengue virus.

Hanson G, Adams J, Kepgang D, Zondagh L, Tem Bueh L, Asante A Front Chem. 2025; 12():1510029.

PMID: 39776767 PMC: 11703810. DOI: 10.3389/fchem.2024.1510029.

Phytoconstituents of Withania somnifera (L.) Dunal (Ashwagandha) unveiled potential cerebroside sulfotransferase inhibitors: insight through virtual screening, molecular dynamics, toxicity, and reverse pharmacophore analysis.

Singh N, Singh A J Biol Eng. 2024; 18(1):59.

PMID: 39444022 PMC: 11515467. DOI: 10.1186/s13036-024-00456-x.

An Overview of Secondary Metabolites from Soft Corals of the Genus over the Five Decades: Chemical Structures, Pharmacological Activities, NMR Data, and Chemical Synthesis.

Liu C, Yang Q, Zhang L, Liang L Mar Drugs. 2024; 22(9).

PMID: 39330283 PMC: 11433205. DOI: 10.3390/md22090402.

Discovery of Potential RAGE inhibitors using Receptor-Based Pharmacophore Modeling, High Throughput Virtual Screening and Docking Studies.

Singh H, Agrawal D J Biotechnol Biomed. 2023; 6(4):501-513.

PMID: 38050632 PMC: 10695404. DOI: 10.26502/jbb.2642-91280112.

References

Wu Y, Wang X, Liu X, Wang Y . Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite. Genome Res. 2003; 13(4):601-16. PMC: 430172. DOI: 10.1101/gr.913403. View

Goldberg D . Plasmodial hemoglobin degradation: an ordered pathway in a specialized organelle. Infect Agents Dis. 1992; 1(4):207-11. View

Fiser A, Sali A . Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol. 2003; 374:461-91. DOI: 10.1016/S0076-6879(03)74020-8. View

Leiriao P, Rodrigues C, Albuquerque S, Mota M . Survival of protozoan intracellular parasites in host cells. EMBO Rep. 2004; 5(12):1142-7. PMC: 1299194. DOI: 10.1038/sj.embor.7400299. View

Irwin J, Shoichet B . ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005; 45(1):177-82. PMC: 1360656. DOI: 10.1021/ci049714+. View

Wang S, Pandey K, Scharfstein J, Whisstock J, Huang R, Jacobelli J . The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family. Structure. 2007; 15(5):535-43. DOI: 10.1016/j.str.2007.03.012. View

Bhattarai A, Ali A, Kachur S, Martensson A, Abbas A, Khatib R . Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007; 4(11):e309. PMC: 2062481. DOI: 10.1371/journal.pmed.0040309. View

Van Wyk A, Gray C, Whibley C, Osoniyi O, Hendricks D, Caira M . Bioactive metabolites from the South African marine mollusk Trimusculus costatus. J Nat Prod. 2008; 71(3):420-5. DOI: 10.1021/np070612y. View

Schmid-Hempel P . Immune defence, parasite evasion strategies and their relevance for 'macroscopic phenomena' such as virulence. Philos Trans R Soc Lond B Biol Sci. 2008; 364(1513):85-98. PMC: 2666695. DOI: 10.1098/rstb.2008.0157. View

10.

Kerr I, Lee J, Pandey K, Harrison A, Sajid M, Rosenthal P . Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J Med Chem. 2009; 52(3):852-7. PMC: 2651692. DOI: 10.1021/jm8013663. View

11.

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

12.

Williams D, Walsh M, Miller N . Studies for the synthesis of xenicane diterpenes. A stereocontrolled total synthesis of 4-hydroxydictyolactone. J Am Chem Soc. 2009; 131(25):9038-45. PMC: 2785454. DOI: 10.1021/ja902677t. View

13.

Ettari R, Bova F, Zappala M, Grasso S, Micale N . Falcipain-2 inhibitors. Med Res Rev. 2009; 30(1):136-67. DOI: 10.1002/med.20163. View

14.

Gardiner D, Skinner-Adams T, Brown C, Andrews K, Stack C, McCarthy J . Plasmodium falciparum: new molecular targets with potential for antimalarial drug development. Expert Rev Anti Infect Ther. 2009; 7(9):1087-98. DOI: 10.1586/eri.09.93. View

15.

Griffin J, Hollingsworth T, Okell L, Churcher T, White M, Hinsley W . Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010; 7(8). PMC: 2919425. DOI: 10.1371/journal.pmed.1000324. View

16.

Shenoy R, Sivaraman J . Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors. J Struct Biol. 2010; 173(1):14-9. DOI: 10.1016/j.jsb.2010.09.007. View

17.

Cai J, Robinson J, Belshaw S, Everett K, Fradera X, van Zeeland M . Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors. Bioorg Med Chem Lett. 2010; 20(23):6890-4. DOI: 10.1016/j.bmcl.2010.10.012. View

18.

Shah F, Mukherjee P, Gut J, Legac J, Rosenthal P, Tekwani B . Identification of novel malarial cysteine protease inhibitors using structure-based virtual screening of a focused cysteine protease inhibitor library. J Chem Inf Model. 2011; 51(4):852-64. DOI: 10.1021/ci200029y. View

19.

Rosenthal P . Falcipains and other cysteine proteases of malaria parasites. Adv Exp Med Biol. 2011; 712:30-48. DOI: 10.1007/978-1-4419-8414-2_3. View

20.

Luker T, Alcaraz L, Chohan K, Blomberg N, Brown D, Butlin R . Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. Bioorg Med Chem Lett. 2011; 21(19):5673-9. DOI: 10.1016/j.bmcl.2011.07.074. View